International union of basic and clinical pharmacology. XCVII. G protein–coupled estrogen receptor and its pharmacologic modulators

Pharmacological Reviews

Volumn 67, Issue 3, 2015, Pages 505-540

  Prossnitz, Eric R ^a   Arterburn, Jeffrey B ^b,c  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c NEW MEXICO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN COUPLED ESTROGEN RECEPTOR; PHYTOESTROGEN; RADIOLIGAND; STEROID; UNCLASSIFIED DRUG; G PROTEIN COUPLED RECEPTOR; LIGAND;

ARTICLE; BINDING AFFINITY; CARDIOVASCULAR SYSTEM; CELL PERMEABILIZATION; HUMAN; IMMUNE SYSTEM; NERVOUS SYSTEM; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR BINDING; REPRODUCTION; WHOLE CELL; ANIMAL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ESTROGENS; FEMALE; HUMANS; LIGANDS; MALE; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STEROIDS;

EID: 84931399806     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.114.009712     Document Type: Article

References (447)

1. Abdelhamid R, Luo J, Vandevrede L, Kundu I, Michalsen B, Litosh VA, Schiefer IT, Gherezghiher T, Yao P, and Qin Z, et al. (2011) Benzothiophene selective estrogen receptor modulators provide neuroprotection by a novel GPR30-dependent mech-anism. ACS Chem Neurosci 2:256–268.
2. Adlanmerini M, Solinhac R, Abot A, Fabre A, Raymond-Letron I, Guihot AL, Boudou F, Sautier L, Vessières E, and Kim SH, et al. (2014) Mutation of the palmitoylation site of estrogen receptor a in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc Natl Acad Sci USA 111:E283–E290.
3. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, Dolce V, Abonante S, Pezzi V, and Maggiolini M (2015) Effects of atrazine onestrogen receptor a- and G protein-coupled receptor 30-mediated signaling and proliferation in cancer cells and cancer-associated fibroblasts. Environ Health Perspect 123:493–499.
4. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, and Andò S, et al. (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17betaestradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67: 1859–1866.
5. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, Lappano R, Pandey DP, Picard D, and Mauro L, et al. (2008) Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149:3799–3808.
6. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, and Harmar AJ, et al.; CGTP Collaborators (2013) The Concise Guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol 170:1449–1458.
7. Allen MC, Gale PA, Hunter AC, Lloyd A, and Hardy SP (2000) Membrane impermeant antioestrogens discriminate between ligand- and voltage-gated cation channels in NG108-15 cells. Biochim Biophys Acta 1509:229–236.
8. Alyea RA, Laurence SE, Kim SH, Katzenellenbogen BS, Katzenellenbogen JA, and Watson CS (2008) The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells. J Neurochem 106:1525–1533.
9. Anchan D, Gafur A, Sano K, Ogawa S, and Vasudevan N (2014) Activation of the GPR30 receptor promotes lordosis in female mice. Neuroendocrinology 100:71–80.
10. Andresen BT (2011) A pharmacological primer of biased agonism. Endocr Metab Immune Disord Drug Targets 11:92–98.
11. Anstead GM, Carlson KE, and Katzenellenbogen JA (1997) The estradiol pharma-cophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62:268–303.
12. Antal MC, Krust A, Chambon P, and Mark M (2008) Sterility and absence of histo-pathological defects in nonreproductive organs of a mouse ERbeta-null mutant. Proc Natl Acad Sci U S A 105:2433–2438.
13. Ariazi EA, Ariazi JL, Cordera F, and Jordan VC (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 6:181–202.
14. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, and Oprea TI, et al. (2010) The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 70:1184–1194.
15. Arterburn JB, Rao KV, and Perry MC (2000) Novel 17a-ethynylestradiol derivatives: Sonogashira couplings using unprotected phenylhydrazines. Tetrahedron Lett 41: 839–842.
16. Balhuizen A, Kumar R, Amisten S, Lundquist I, and Salehi A (2010) Activation of G protein-coupled receptor 30 modulates hormone secretion and counteracts cytokine-induced apoptosis in pancreatic islets of female mice. Mol Cell Endocrinol 320:16–24.
17. Baltgalvis KA, Greising SM, Warren GL, and Lowe DA (2010) Estrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle. PLoS ONE 5:e10164.
18. Banères JL and Mouillac B (2012) [Handling G-protein-coupled receptors: expression, purification and in vitro stabilization]. Med Sci (Paris) 28:837–844.
19. Banerjee S, Chambliss KL, Mineo C, and Shaul PW (2014) Recent insights into non-nuclear actions of estrogen receptor alpha. Steroids 81:64–69.
20. Baquedano MS, Saraco N, Berensztein E, Pepe C, Bianchini M, Levy E, Gofii J, Rivarola MA, and Belgorosky A (2007) Identification and developmental changes of aromatase and estrogen receptor expression in prepubertal and pubertal human adrenal tissues. J Clin Endocrinol Metab 92:2215–2222.
21. Baranda-Avila N, Mendoza-Rodríguez CA, Morimoto S, Camacho-Arroyo I, Guerra-Araiza C, Langley E, and Cerbón M (2013) Agonistic activity of ICI 182 780 on activation of GSK 3b/AKT pathway in the rat uterus during the estrous cycle. Steroids 78:717–725.
22. Barton M and Meyer MR (2009) Postmenopausal hypertension: mechanisms and therapy. Hypertension 54:11–18.
23. Barton M and Prossnitz ER (2015) Emerging roles of GPER in diabetes and ath-erosclerosis. Trends Endocrinol Metab 26:185–192.
24. Bean LA, Ianov L, and Foster TC (2014) Estrogen receptors, the hippocampus, and memory. Neuroscientist 20:534–545.
25. Benagiano G, Bastianelli C, and Farris M (2006) Contraception today. Ann NYAcad Sci 1092:1–32.
26. Bennett TA, Key TA, Gurevich VV, Neubig R, Prossnitz ER, and Sklar LA (2001) Real-time analysis of G protein-coupled receptor reconstitution in a solubilized system. J Biol Chem 276:22453–22460.
27. Biegon A, Brewster M, Degani H, Pop E, Somjen D, and Kaye AM (1996) A permanently charged tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. Cancer Res 56:4328–4331.
28. Binder M (1984) Oestradiol-BSA conjugates for receptor histochemistry: problems of stability and interactions with cytosol. Histochem J 16:1003–1023.
29. Blair IA (2010) Analysis of estrogens in serum and plasma from postmenopausal women: past present, and future. Steroids 75:297–306.
30. Blair RM, Fang H, Branham WS, Hass BS, Dial SL, Moland CL, Tong W, Shi L, Perkins R, and Sheehan DM (2000) The estrogen receptor relative binding affinities of 188 natural and xenochemicals: structural diversity of ligands. Toxicol Sci 54:138–153.
31. Blasko E, Haskell CA, Leung S, Gualtieri G, Halks-Miller M, Mahmoudi M, Dennis MK, Prossnitz ER, Karpus WJ, and Horuk R (2009) Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. JNeuroimmunol 214:67–77.
32. Bodhankar S and Offner H (2011) GPR30 Forms an Integral Part of E2-Protective Pathway in Experimental Autoimmune Encephalomyelitis. Immunol Endocr Metab Agents Med Chem 11:262–274.
33. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, and Sklar LA, et al. (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2:207–212.
34. Bonds RS and Midoro-Horiuti T (2013) Estrogen effects in allergy and asthma. Curr Opin Allergy Clin Immunol 13:92–99.
35. Bopassa JC, Eghbali M, Toro L, and Stefani E (2010) A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 298:H16–H23.
36. Bopassa JC, Leeb-Lundberg LF, Olde B, Toro L, and Stefani E (2011) Loss of rapid estrogen-induced cardioprotection in GPER-/- mice after ischemia and reperfusion. Biophys J 100:294a–295a.
37. Bopassa JC, Lu R, Singh H, Olde B, Krust A, Leeb-Lundberg LF, Toro L, and Stefani E (2012a) G protein-coupled estrogen receptor 1, but not estrogen receptors alpha and beta, mediates rapid estrogen-induced cardioprotection during ischemia/ reperfusion injury in male mice. Biophys J 102:141a.
38. Bopassa JC, Lu R, Singh H, Zilberstein NF, Olde B, Krust A, Leeb-Lundberg LF, Toro L, and Stefani E (2012b) Rapid activation of G protein-coupled estrogen receptor 1 protects the heart against ischemia-reperfusion injury by inhibiting the mPTP opening via PKC/AKT/ERK/GSK-3b pathways. Circ Res 111:A213.
39. Bourque M, Morissette M, and Di Paolo T (2014) Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1 methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Neurobiol Aging 35:2347–2356.
40. Brailoiu GC, Benamar K, Arterburn JB, Gao E, Rabinowitz JE, Koch WJ, and Brailoiu E (2013) Aldosterone increases cardiac vagal tone via GPER activation. J Physiol 591:4223–4235.
41. Brailoiu E, Dun SL, Brailoiu GC, Mizuo K, Sklar LA, Oprea TI, Prossnitz ER, and Dun NJ (2007) Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol 193:311–321.
42. Broughton BR, Brait VH, Guida E, Lee S, Arumugam TV, Gardiner-Mann CV, Miller AA, Tang SC, Drummond GR, and Sobey CG (2013) Stroke increases G proteincoupled estrogen receptor expression in the brain of male but not female mice. Neurosignals 21:229–239
43. Broughton BR, Brait VH, Kim HA, Lee S, Chu HX, Gardiner-Mann CV, Guida E, Evans MA, Miller AA, and Arumugam TV, et al. (2014) Sex-dependent effects of G protein-coupled estrogen receptor activity on outcome after ischemic stroke. Stroke 45:835–841.
44. Brunsing RL, Owens KS, and Prossnitz ER (2013) The G protein-coupled estrogen receptor (GPER) agonist G-1 expands the regulatory T-cell population under TH17 polarizing conditions. J Immunother 36:190–196.
45. Brunsing RL and Prossnitz ER (2011) Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1. Immunology 134:93–106.
46. Bulayeva NN, Gametchu B, and Watson CS (2004) Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Steroids 69:181–192.
47. Burai R, Ramesh C, Shorty M, Curpan R, Bologa C, Sklar LA, Oprea T, Prossnitz ER, and Arterburn JB (2010) Highly efficient synthesis and characterization of the GPR30-selective agonist G-1 and related tetrahydroquinoline analogs. Org Biolmol Chem 8:2252–2259.
48. Burai R, Ramesh C, Nayak TK, Dennis MK, Bryant BK, Prossnitz ER, and Arterburn JB (2012) Synthesis and characterization of tricarbonyl-Re/Tc(I) chelate probes targeting the G protein-coupled estrogen receptor GPER/GPR30. PLoS ONE 7: e46861.
49. Burris TP, Solt LA, Wang Y, Crumbley C, Banerjee S, Griffett K, Lundasen T, Hughes T, and Kojetin DJ (2013) Nuclear receptors and their selective pharmacologic modulators. Pharmacol Rev 65:710–778.
50. Cabas I, Rodenas MC, Abellán E, Meseguer J, Mulero V, and García-Ayala A (2013) Estrogen signaling through the G protein-coupled estrogen receptor regulates granulocyte activation in fish. J Immunol 191:4628–4639.
51. Calabrese EJ (2001) Estrogen and related compounds: biphasic dose responses. Crit Rev Toxicol 31:503–515.
52. Callard GV, Tarrant AM, Novillo A, Yacci P, Ciaccia L, Vajda S, Chuang GY, Kozakov D, Greytak SR, and Sawyer S, et al. (2011) Evolutionary origins of the estrogen signaling system: insights from amphioxus. J Steroid Biochem Mol Biol 127: 176–188.
53. Carmeci C, Thompson DA, Ring HZ, Francke U, and Weigel RJ (1997) Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45:607–617.
54. Carroll JS and Brown M (2006) Estrogen receptor target gene: an evolving concept. Mol Endocrinol 20:1707–1714.
55. Carroll VM, Jeyakumar M, Carlson KE, and Katzenellenbogen JA (2012) Diary-lpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor beta-selective ligands. J Med Chem 55:528–537.
56. Casals-Casas C and Desvergne B (2011) Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol 73:135–162.
57. Catalano S, Giordano C, Panza S, Chemi F, Bonofiglio D, Lanzino M, Rizza P, Romeo F, Fuqua SA, and Maggiolini M, et al. (2014) Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Res Treat 146:273–285.
58. Chakrabarti S and Davidge ST (2012) G-protein coupled receptor 30 (GPR30): a novel regulator of endothelial inflammation. PLoS ONE 7:e52357.
59. Chakrabarti S, Morton JS, and Davidge ST (2014) Mechanisms of estrogen effects on the endothelium: an overview. Can J Cardiol 30:705–712.
60. Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, Korach KS, Thomas GD, Mineo C, Yuhanna IS, and Kim SH, et al. (2010) Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 120:2319–2330.
61. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, and Lau KM (2010) Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G (2) cell-cycle arrest. Cell Death Differ 17:1511–1523.
62. Charn TH, Liu ET, Chang EC, Lee YK, Katzenellenbogen JA, and Katzenellenbogen BS (2010) Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Mol Endocrinol 24: 47–59.
63. Chaudhri RA, Schwartz N, Elbaradie K, Schwartz Z, and Boyan BD (2014) Role of ERa36 in membrane-associated signaling by estrogen. Steroids 81:74–80.
64. Chen Y, Li Z, He Y, Shang D, Pan J, Wang H, Chen H, Zhu Z, Wan L, and Wang X (2014) Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cellmatrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol 275: 176–181.
65. Cheng SB, Dong J, Pang Y, LaRocca J, Hixon M, Thomas P, and Filardo EJ (2014) Anatomical location and redistribution of G protein-coupled estrogen receptor-1 during the estrus cycle in mouse kidney and specific binding to estrogens but not aldosterone. Mol Cell Endocrinol 382:950–959.
66. Cheng SB, Graeber CT, Quinn JA, and Filardo EJ (2011a) Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/ GPER) from the plasma membrane towards the nucleus. Steroids 76:892–896.
67. Cheng SB, Quinn JA, Graeber CT, and Filardo EJ (2011b) Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a transGolgi-proteasome pathway. J Biol Chem 286:22441–22455.
68. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108.
69. Chevalier N, Bouskine A, and Fenichel P (2012a) Bisphenol A promotes testicular seminoma cell proliferation through GPER/GPR30. Int J Cancer 130:241–242.
70. Chevalier N, Paul-Bellon R, Camparo P, Michiels JF, Chevallier D, and Fénichel P (2014) Genetic variants of GPER/GPR30, a novel estrogen-related G protein receptor, are associated with human seminoma. Int J Mol Sci 15:1574–1589.
71. Chevalier N, Vega A, Bouskine A, Siddeek B, Michiels JF, Chevallier D, and Fénichel P (2012b) GPR30, the non-classical membrane G protein related estrogen receptor, is overexpressed in human seminoma and promotes seminoma cell proliferation. PLoS ONE 7:e34672.
72. Chimento A, Casaburi I, Bartucci M, Patrizii M, Dattilo R, Avena P, Andò S, Pezzi V, and Sirianni R (2013) Selective GPER activation decreases proliferation and activates apoptosis in tumor Leydig cells. Cell Death Dis 4:e747.
73. Chimento A, Casaburi I, Rosano C, Avena P, De Luca A, Campana C, Martire E, Santolla MF, Maggiolini M, and Pezzi V, et al. (2014a) Oleuropein and hydroxytyrosol activate GPER/ GPR30-dependent pathways leading to apoptosis of ER-negative SKBR3 breast cancer cells. Mol Nutr Food Res 58:478–489.
74. Chimento A, Sirianni R, Casaburi I, and Pezzi V (2014b) Role of estrogen receptors and G protein-coupled estrogen receptor in regulation of hypothalamus-pituitarytestis axis and spermatogenesis. Front Endocrinol (Lausanne) 5:1.
75. Chimento A, Sirianni R, Zolea F, Bois C, Delalande C, Andò S, Maggiolini M, Aquila S, Carreau S, and Pezzi V (2011) Gper and ESRs are expressed in rat round spermatids and mediate oestrogen-dependent rapid pathways modulating expression of cyclin B1 and Bax. Int J Androl 34:420–429.
76. Chourasia TK, Pang Y, and Thomas P (2015) The catecholestrogen, 2 hydroxyestradiol-17beta, acts as a G Protein-Coupled Estrogen Receptor 1 (GPER/ GPR30) antagonist to promote the resumption of meiosis in zebrafish oocytes. Biol Reprod 92:69.
77. Claing A and Laporte SA (2005) Novel roles for arrestins in G protein-coupled receptor biology and drug discovery. Curr Opin Drug Discov Devel 8:585–589.
78. Cordera F and Jordan VC (2006) Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol 33:631–641.
79. Couse JF and Korach KS (2001) Contrasting phenotypes in reproductive tissues of female estrogen receptor null mice. Ann N YAcad Sci 948:1–8.
80. Craig Jordan V, Lewis-Wambi J, Kim H, Cunliffe H, Ariazi E, Sharma CG, Shupp HA, and Swaby R (2007) Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast 16 (Suppl 2):S105–S113.
81. Cunningham M and Gilkeson G (2011) Estrogen receptors in immunity and auto-immunity. Clin Rev Allergy Immunol 40:66–73.
82. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, and Gustafsson JA (2006) International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 58:773–781.
83. Dai D, Bradford AP, and Prossnitz ER (2014) Endometrial cancer: molecular and cellular basis of tumor development, novel biomarkers and therapeutic agents, and innovative research approaches. Obstet Gynecol Int 2014:710405.
84. Davis KE, Carstens EJ, Irani BG, Gent LM, Hahner LM, and Clegg DJ (2014) Sexually dimorphic role of G protein-coupled estrogen receptor (GPER) in modulating energy homeostasis. Horm Behav 66:196–207.
85. De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, and Maggiolini M (2013) HIF-1a/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res 15:R64.
86. De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S, and Maggiolini M (2014) GPER mediates activation of HIF1a/VEGF signaling by estrogens. Cancer Res 74:4053–4064.
87. Delbeck M, Golz S, Vonk R, Janssen W, Hucho T, Isensee J, Schäfer S, and Otto C (2011) Impaired left-ventricular cardiac function in male GPR30-deficient mice. Mol Med Rep 4:37–40.
88. Deliu E, Brailoiu GC, Arterburn JB, Oprea TI, Benamar K, Dun NJ, and Brailoiu E (2012) Mechanisms of G protein-coupled estrogen receptor-mediated spinal noci-ception. J Pain 13:742–754.
89. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, and Deliu E, et al. (2009) In vivo effects of a GPR30 antagonist. Nat Chem Biol 5:421–427.
90. Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi S, and Sklar LA, et al. (2011) Identification of a GPER/ GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol 127:358–366.
91. De Goeij AF, van Zeeland JK, Beek CJ, and Bosman FT (1986) Steroid-bovine serum albumin conjugates: molecular characterization and their interaction with androgen and estrogen receptors. J Steroid Biochem 24:1017–1031.
92. De Marco P, Romeo E, Vivacqua A, Malaguarnera R, Abonante S, Romeo F, Pezzi V, Belfiore A, and Maggiolini M (2014) GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocr Relat Cancer 21:739–753.
93. De Paula ML, Rodrigues DH, Teixeira HC, Barsante MM, Souza MA, and Ferreira AP (2008) Genistein down-modulates pro-inflammatory cytokines and reverses clinical signs of experimental autoimmune encephalomyelitis. Int Immunopharmacol 8:1291–1297.
94. Deschamps AM and Murphy E (2008) Activation of a novel estrogen receptor, GPR30, is cardioprotective in the rat. Circulation 118:S357–S358.
95. Deschamps AM and Murphy E (2009) Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 297: H1806–H1813.
96. Dick GM, Hunter AC, and Sanders KM (2002) Ethylbromide tamoxifen, a membrane-impermeant antiestrogen, activates smooth muscle calcium-activated large-conductance potassium channels from the extracellular side. Mol Pharmacol 61: 1105–1113.
97. Dietze EC, Troch MM, Bean GR, Heffner JB, Bowie ML, Rosenberg P, Ratliff B, and Seewaldt VL (2004) Tamoxifen and tamoxifen ethyl bromide induce apoptosis in acutely damaged mammary epithelial cells through modulation of AKT activity. Oncogene 23:3851–3862.
98. Ding Q, Gros R, Limbird LE, Chorazyczewski J, and Feldman RD (2009) Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol Cell Physiol 297:C1178–C1187.
99. Dong S, Terasaka S, and Kiyama R (2011) Bisphenol A induces a rapid activation of Erk1/2 through GPR30 in human breast cancer cells. Environ Pollut 159:212–218.
100. Dong WH, Chen JC, He YL, Xu JJ, and Mei YA (2013) Resveratrol inhibits K(v)2.2 currents through the estrogen receptor GPR30-mediated PKC pathway. Am J Physiol Cell Physiol 305:C547–C557.
101. Dun SL, Brailoiu GC, Gao X, Brailoiu E, Arterburn JB, Prossnitz ER, Oprea TI, and Dun NJ (2009) Expression of estrogen receptor GPR30 in the rat spinal cord and in autonomic and sensory ganglia. J Neurosci Res 87:1610–1619.
102. Edwards DP (2005) Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67:335–376.
103. Etgen AM, Jover-Mengual T, and Zukin RS (2011) Neuroprotective actions of estradiol and novel estrogen analogs in ischemia: translational implications. Front Neuroendocrinol 32:336–352.
104. Evron T, Daigle TL, and Caron MG (2012) GRK2: multiple roles beyond G protein-coupled receptor desensitization. Trends Pharmacol Sci 33:154–164.
105. Falkenstein E, Tillmann HC, Christ M, Feuring M, and Wehling M (2000) Multiple actions of steroid hormones—a focus on rapid, nongenomic effects. Pharmacol Rev 52:513–556.
106. Faulds MH, Zhao C, Dahlman-Wright K, and Gustafsson JA (2012) The diversity of sex steroid action: regulation of metabolism by estrogen signaling. J Endocrinol 212:3–12.
107. Feng Y and Gregor P (1997) Cloning of a novel member of the G protein-coupled receptor family related to peptide receptors. Biochem Biophys Res Commun 231: 651–654.
108. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, and Thomas P (2007) Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 148:3236–3245.
109. Filardo EJ (2002) Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80:231–238.
110. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, and Sabo E (2006) Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12:6359–6366.
111. Filardo EJ, Quinn JA, Bland KI, and Frackelton AR Jr (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14:1649–1660.
112. Filardo EJ, Quinn JA, Frackelton AR Jr, and Bland KI (2002) Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16:70–84.
113. Filardo EJ and Thomas P (2005) GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 16:362–367.
114. Filardo EJ and Thomas P (2012) Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology 153:2953–2962.
115. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Jones BF, Barry CV, Wulczyn KE, and Thomas BJ, et al. (2013) Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 369:1011–1022.
116. Fowler AM, Chan SR, Sharp TL, Fettig NM, Zhou D, Dence CS, Carlson KE, Jeyakumar M, Katzenellenbogen JA, and Schreiber RD, et al. (2012) Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med 53:1119–1126.
117. Franco R, Boscia F, Gigantino V, Marra L, Esposito F, Ferrara D, Pariante P, Botti G, Caraglia M, and Minucci S, et al. (2011) GPR30 is overexpressed in post-puberal testicular germ cell tumors. Cancer Biol Ther 11:609–613.
118. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, and Katzenellenbogen BS (2004) Selective estrogen receptor modulators: discrimination of agonistic versus antag-onistic activities by gene expression profiling in breast cancer cells. Cancer Res 64: 1522–1533.
119. Fucic A, Gamulin M, Ferencic Z, Katic J, Krayer von Krauss M, Bartonova A, and Merlo DF (2012) Environmental exposure to xenoestrogens and oestrogen related cancers: reproductive system, breast, lung, kidney, pancreas, and brain. Environ Health 11 (Suppl 1):S8.
120. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, Buys SS, Isaacs C, Keefer LK, and Veenstra TD, et al. (2012) Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 104:326–339.
121. Funakoshi T, Yanai A, Shinoda K, Kawano MM, and Mizukami Y (2006) G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun 346:904–910.
122. Gaido KW, Maness SC, McDonnell DP, Dehal SS, Kupfer D, and Safe S (2000) In-teraction of methoxychlor and related compounds with estrogen receptor alpha and beta, and androgen receptor: structure-activity studies. Mol Pharmacol 58: 852–858.
123. Gajecki M (2002) Zearalenone—undesirable substances in feed. Pol J Vet Sci 5: 117–122.
124. Gallo D, De Stefano I, Grazia Prisco M, Scambia G, and Ferrandina G (2012) Estrogen receptor beta in cancer: an attractive target for therapy. Curr Pharm Des 18:2734–2757.
125. Gao F, Ma X, Ostmann AB, and Das SK (2011) GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERa) phosphorylation signals. Endocrinology 152:1434–1447.
126. Gavin KM, Cooper EE, and Hickner RC (2013) Estrogen receptor protein content is different in abdominal than gluteal subcutaneous adipose tissue of overweight-to-obese premenopausal women. Metabolism 62:1180–1188.
127. Ge LC, Chen ZJ, Liu HY, Zhang KS, Liu H, Huang HB, Zhang G, Wong CK, Giesy JP, and Du J, et al. (2014) Involvement of activating ERK1/2 through G protein coupled receptor 30 and estrogen receptor a/b in low doses of bisphenol A promoting growth of Sertoli TM4 cells. Toxicol Lett 226:81–89.
128. Gingerich S, Kim GL, Chalmers JA, Koletar MM, Wang X, Wang Y, and Belsham DD (2010) Estrogen receptor a and G-protein coupled receptor 30 mediate the neuroprotective effects of 17O-estradiol in novel murine hippocampal cell models. Neuroscience 170:54–66.
129. Giraldo J, Serra J, Roche D, and Rovira X (2007) Assessing receptor affinity for inverse agonists: Schild and Cheng-Prusoff methods revisited. Curr Drug Targets 8:197–202.
130. Goswami C, Kuhn J, Dina OA, Fernández-Ballester G, Levine JD, Ferrer-Montiel A, and Hucho T (2011) Estrogen destabilizes microtubules through an ion-conductivity-independent TRPV1 pathway. JNeurochem 117:995–1008.
131. Goupil E, Laporte SA, and Hébert TE (2012) Functional selectivity in GPCR signaling: understanding the full spectrum of receptor conformations. Mini Rev Med Chem 12:817–830.
132. Grimsey N, Soto AG, and Trejo J (2011) Regulation of protease-activated receptor signaling by post-translational modifications. IUBMB Life 63:403–411.
133. Gros R, Ding Q, Liu B, Chorazyczewski J, and Feldman RD (2013) Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Am J Physiol Cell Physiol 304:C532–C540.
134. Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, and Feldman RD (2011) GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension 57:442–451.
135. Gurevich EV, Tesmer JJ, Mushegian A, and Gurevich VV (2012) G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther 133:40–69.
136. Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, and Minotti R, et al. (2009) Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 104: 288–291.
137. Hager GL, Lim CS, Elbi C, and Baumann CT (2000) Trafficking of nuclear receptors in living cells. J Steroid Biochem Mol Biol 74:249–254.
138. Hammond R and Gibbs RB (2011) GPR30 is positioned to mediate estrogen effects on basal forebrain cholinergic neurons and cognitive performance. Brain Res 1379: 53–60.
139. Hammond R, Nelson D, and Gibbs RB (2011) GPR30 co-localizes with cholinergic neurons in the basal forebrain and enhances potassium-stimulated acetylcholine release in the hippocampus. Psychoneuroendocrinology 36:182–192.
140. Han G, Li F, Yu X, and White RE (2013) GPER: a novel target for non-genomic estrogen action in the cardiovascular system. Pharmacol Res 71:53–60.
141. Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, and Katzenellenbogen BS (2006) Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20:491–502.
142. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, and Katzenellenbogen BS (2003) Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating trans-activation or transrepression. Mol Cell Endocrinol 206:13–22.
143. Harris HA, Katzenellenbogen JA, and Katzenellenbogen BS (2002) Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 143:4172–4177.
144. Hazell GG, Yao ST, Roper JA, Prossnitz ER, O’Carroll AM, and Lolait SJ (2009) Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J Endocrinol 202: 223–236.
145. He YY, Cai B, Yang YX, Liu XL, and Wan XP (2009) Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ ERK mitogen-activated protein kinase pathway. Cancer Sci 100:1051–1061.
146. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, and Warner M, et al. (2007) Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87:905–931.
147. Helsen C and Claessens F (2014) Looking at nuclear receptors from a new angle. Mol Cell Endocrinol 382:97–106.
148. Hengstler JG, Foth H, Gebel T, Kramer PJ, Lilienblum W, Schweinfurth H, Völkel W, Wollin KM, and Gundert-Remy U (2011) Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. Crit Rev Toxicol 41:263–291.
149. Henic E, Noskova V, Høyer-Hansen G, Hansson S, and Casslén B (2009) Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the Gprotein-coupled receptor 30 in ovarian cancer cells. Int J Gynecol Cancer 19: 214–222.
150. Heublein S, Lenhard M, Vrekoussis T, Schoepfer J, Kuhn C, Friese K, Makrigiannakis A, Mayr D, and Jeschke U (2012) The G-protein-coupled estrogen receptor (GPER) is expressed in normal human ovaries and is upregulated in ovarian endometriosis and pelvic inflammatory disease involving the ovary. Reprod Sci 19: 1197–1204.
151. Hewitt SC, Deroo BJ, Hansen K, Collins J, Grissom S, Afshari CA, and Korach KS (2003) Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen. Mol Endocrinol 17:2070–2083.
152. Hine R (1999) Membrane, in The Facts on File Dictionary of Biology, 3rd ed., p 198, Worth Publishers, New York.
153. Hofmeister MV, Damkier HH, Christensen BM, Olde B, Fredrik Leeb-Lundberg LM, Fenton RA, Praetorius HA, and Praetorius J (2012) 170-Estradiol induces non-genomic effects in renal intercalated cells through G protein-coupled estrogen re-ceptor 1. Am J Physiol Renal Physiol 302:F358–F368.
154. Holm A, Grände PO, Luduefia RF, Olde B, Prasad V, Leeb-Lundberg LM, and Nilsson BO (2012) The G protein-coupled oestrogen receptor 1 agonist G-1 disrupts endothelial cell microtubule structure in a receptor-independent manner. Mol Cell Biochem 366:239–249.
155. Holm A and Nilsson BO (2013) Identification and characterization of new mechanisms in vascular oestrogen signalling. Basic Clin Pharmacol Toxicol 113:287–293.
156. Howell A, Osborne CK, Morris C, and Wakeling AE (2000) ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer 89:817–825.
157. Hsieh YC, Yu HP, Frink M, Suzuki T, Choudhry MA, Schwacha MG, and Chaudry IH (2007) G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage. Am J Pathol 170:1210–1218.
158. Huang P, Chandra V, and Rastinejad F (2010) Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol 72:247–272.
159. Hubbard RE, Pike AC, Brzozowski AM, Walton J, Bonn T, Gustafsson JA, and Carlquist M (2000) Structural insights into the mechanisms of agonism and antagonism in oestrogen receptor isoforms. Eur J Cancer 36 (Suppl 4):S17–S18.
160. Huhtinen K, Desai R, Ståhle M, Salminen A, Handelsman DJ, Perheentupa A, and Poutanen M (2012) Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab 97:4228–4235.
161. Huryn DM, Resnick LO, and Wipf P (2013) Contributions of academic laboratories to the discovery and development of chemical biology tools. J Med Chem 56: 7161–7176.
162. Ignatov A, Ignatov T, Roessner A, Costa SD, and Kalinski T (2010) Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123:87–96.
163. Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD, and Kalinski T (2011a) G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 128:457–466.
164. Ignatov T, Eggemann H, Semczuk A, Smith B, Bischoff J, Roessner A, Costa SD, Kalinski T, and Ignatov A (2011b) Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. Am J Obstet Gynecol 203:595.
165. Ignatov T, Modl S, Thulig M, Weiflenborn C, Treeck O, Ortmann O, Zenclussen A, Costa SD, Kalinski T, and Ignatov A (2013a) GPER-1 acts as a tumor suppressor in ovarian cancer. J Ovarian Res 6:51.
166. Ignatov T, Weiflenborn C, Poehlmann A, Lemke A, Semczuk A, Roessner A, Costa SD, Kalinski T, and Ignatov A (2013b) GPER-1 expression decreases during breast cancer tumorigenesis. Cancer Invest 31:309–315.
167. Imai Y, Youn MY, Inoue K, Takada I, Kouzmenko A, and Kato S (2013) Nuclear receptors in bone physiology and diseases. Physiol Rev 93:481–523.
168. Isensee J, Meoli L, Zazzu V, Nabzdyk C, Witt H, Soewarto D, Effertz K, Fuchs H, Gailus-Durner V, and Busch D, et al. (2009) Expression pattern of G protein-coupled receptor 30 in LacZ reporter mice. Endocrinology 150:1722–1730.
169. Jarman M, Leung OT, Leclercq G, Devleeschouwer N, Stoessel S, Coombes RC, and Skilton RA (1986) Analogues of tamoxifen: the role of the basic side-chain. Applications of a whole-cell oestrogen-receptor binding assay to N-oxides and quaternary salts. Anticancer Drug Des 1:259–268.
170. Jensen EV and DeSombre ER (1973) Estrogen-receptor interaction. Science 182: 126–134.
171. Jensen EV and Jacobson HI (1962) Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18:387–414.
172. Jensen EV and Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9:1980–1989.
173. Jordan VC (2000) Tamoxifen: a personal retrospective. Lancet Oncol 1:43–49.
174. Jordan VC (2007) SERMs: meeting the promise of multifunctional medicines. JNatl Cancer Inst 99:350–356.
175. Kajta M, Litwa E, Rzemieniec J, Wnuk A, Lason W, Zelek-Molik A, Nalepa I, Grzegorzewska-Hiczwa M, Tokarski K, and Golas A, et al. (2014) Isomer-nonspecific action of dichlorodiphenyltrichloroethane on aryl hydrocarbon receptor and G-protein-coupled receptor 30 intracellular signaling in apoptotic neuronal cells. Mol Cell Endocrinol 392:90–105.
176. Kajta M, Rzemieniec J, Litwa E, Lason W, Lenartowicz M, Krzeptowski W, and Wojtowicz AK (2013) The key involvement of estrogen receptor 0 and Gprotein-coupled receptor 30 in the neuroprotective action of daidzein. Neuroscience 238:345–360.
177. Kamanga-Sollo E, White ME, Chung KY, Johnson BJ, and Dayton WR (2008) Potential role of G-protein-coupled receptor 30 (GPR30) in estradiol-17betastimulated IGF-I mRNA expression in bovine satellite cell cultures. Domest Anim Endocrinol 35:254–262.
178. Kang K, Lee SB, Jung SH, Cha KH, Park WD, Sohn YC, and Nho CW (2009) Tectoridin, a poor ligand of estrogen receptor alpha, exerts its estrogenic effects via an ERK-dependent pathway. Mol Cells 27:351–357.
179. Kang S, Liu Y, Sun D, Zhou C, Liu A, Xu C, Hao Y, Li D, Yan C, and Sun H (2012) Chronic activation of the G protein-coupled receptor 30 with agonist G-1 attenuates heart failure. PLoS ONE 7:e48185.
180. Kangas L (1992) Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31:143–146.
181. Katritch V, Cherezov V, and Stevens RC (2013) Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol 53:531–556.
182. Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, et al. (2000) Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res 55:163–193; discussion 194–195.
183. Katzenellenbogen JA (1995) Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med 36(6, Suppl)8S–13S.
184. Katzenellenbogen JA, Carlson KE, Heiman DF, and Goswami R (1980) Receptor-binding radiopharmaceuticals for imaging breast tumors: estrogen-receptor inter-actions and selectivity of tissue uptake of halogenated estrogen analogs. J Nucl Med 21:550–558.
185. Katzenellenbogen JA, Welch MJ, and Dehdashti F (1997) The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 17 (3B):1573–1576.
186. Kelly MJ and Rønnekleiv OK (2013) A selective membrane estrogen receptor agonist maintains autonomic functions in hypoestrogenic states. Brain Res 1514:75–82.
187. Kenakin T (2013) New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2. Br J Pharmacol 168:554–575.
188. Kenakin TP (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 165:1659–1669.
189. Key TA, Bennett TA, Foutz TD, Gurevich VV, Sklar LA, and Prossnitz ER (2001) Regulation of formyl peptide receptor agonist affinity by reconstitution with arrestins and heterotrimeric G proteins. J Biol Chem 276:49204–49212.
190. Key TA, Foutz TD, Gurevich VV, Sklar LA, and Prossnitz ER (2003) N-formyl peptide receptor phosphorylation domains differentially regulate arrestin and agonist affinity. J Biol Chem 278:4041–4047.
191. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, and Welch MJ (1984) Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 25:1212–1221.
192. Kim HY, Sohn J, Wijewickrama GT, Edirisinghe P, Gherezghiher T, Hemachandra M, Lu PY, Chandrasena RE, Molloy ME, and Tonetti DA, et al. (2010) Click synthesis of estradiol-cyclodextrin conjugates as cell compartment selective estrogens. Bioorg Med Chem 18:809–821.
193. Kim KH and Bender JR (2009) Membrane-initiated actions of estrogen on the en-dothelium. Mol Cell Endocrinol 308:3–8.
194. Kim KH, Toomre D, and Bender JR (2011) Splice isoform estrogen receptors as integral transmembrane proteins. Mol Biol Cell 22:4415–4423.
195. Kim SH and Katzenellenbogen JA (2006) Hormone-PAMAM dendrimer conjugates: polymer dynamics and tether structure affect ligand access to receptors. Angew Chem Int Ed Engl 45:7243–7248.
196. Kisler K, Chow RH, and Dominguez R (2013) Fluorescently-labeled estradiol in-ternalization and membrane trafficking in live N-38 neuronal cells visualized with total internal reflection fluorescence microscopy. J Steroids Horm Sci Suppl 12.
197. Knowlton AA and Lee AR (2012) Estrogen and the cardiovascular system. Pharmacol Ther 135:54–70.
198. Koganti S, Snyder R, Gumaste U, Karamyan VT, and Thekkumkara T (2013) 2 Methoxyestradiol binding of GPR30 down-regulates angiotensin AT receptor. Eur J Pharmacol 723C:131–140.
199. Kojima H, Katsura E, Takeuchi S, Niiyama K, and Kobayashi K (2004) Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. Environ Health Perspect 112:524–531.
200. Korach KS, Chae K, Levy LA, Duax WL, and Sarver PJ (1989) Diethylstilbestrol metabolites and analogs. Stereochemical probes for the estrogen receptor binding site. J Biol Chem 264:5642–5647.
201. Korach KS, Metzler M, and McLachlan JA (1978) Estrogenic activity in vivo and in vitro of some diethylstilbestrol metabolites and analogs. Proc Natl Acad Sci USA 75:468–471.
202. Kruse AC, Hu J, Kobilka BK, and Wess J (2014) Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development. Curr Opin Pharmacol 16:24–30.
203. Kuhn J, Dina OA, Goswami C, Suckow V, Levine JD, and Hucho T (2008) GPR30 estrogen receptor agonists induce mechanical hyperalgesia in the rat. Eur J Neurosci 27:1700–1709.
204. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, and Gustafsson JA (1997) Comparison of the ligand binding specificity and transcript tissue distri-bution of estrogen receptors alpha and beta. Endocrinology 138:863–870.
205. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, and Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93: 5925–5930.
206. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, and Gustafsson JA (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139:4252–4263.
207. Kumar R, Balhuizen A, Amisten S, Lundquist I, and Salehi A (2011) Insulinotropic and antidiabetic effects of 170-estradiol and the GPR30 agonist G-1 on human pancreatic islets. Endocrinology 152:2568–2579.
208. Kumar S, Saradhi M, Chaturvedi NK, and Tyagi RK (2006) Intracellular localization and nucleocytoplasmic trafficking of steroid receptors: an overview. Mol Cell Endocrinol 246:147–156.
209. Kushnir MM, Rockwood AL, Bergquist J, Varshavsky M, Roberts WL, Yue B, Bunker AM, and Meikle AW (2008) High-sensitivity tandem mass spectrometry assay for serum estrone and estradiol. Am J Clin Pathol 129:530–539.
210. Kvingedal AM and Smeland EB (1997) A novel putative G-protein-coupled receptor expressed in lung, heart and lymphoid tissue. FEBS Lett 407:59–62.
211. Lakhani NJ, Sarkar MA, Venitz J, and Figg WD (2003) 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23:165–172.
212. Lam HM, Ouyang B, Chen J, Ying J, Wang J, Wu CL, Jia L, Medvedovic M, Vessella RL, and Ho SM (2014) Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. Endocr Relat Cancer 21:903–914.
213. Lappano R, Pisano A, and Maggiolini M (2014) GPER Function in Breast Cancer: An Overview. Front Endocrinol (Lausanne) 5:66.
214. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, and Maggiolini M (2010) Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol 320:162–170.
215. Lappano R, Rosano C, Santolla MF, Pupo M, De Francesco EM, De Marco P, Ponassi M, Spallarossa A, Ranise A, and Maggiolini M (2012a) Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr Cancer Drug Targets 12:531–542.
216. Lappano R, Santolla MF, Pupo M, Sinicropi MS, Caruso A, Rosano C, and Maggiolini M (2012b) MIBE acts as antagonist ligand of both estrogen receptor a and GPER in breast cancer cells. Breast Cancer Res 14:R12.
217. La Rosa P, Pesiri V, Leclercq G, Marino M, and Acconcia F (2012) Palmitoylation regulates 170-estradiol-induced estrogen receptor-a degradation and transcriptional activity. Mol Endocrinol 26:762–774.
218. Lathe R and Kotelevtsev Y (2014) Steroid signaling: ligand-binding promiscuity, molecular symmetry, and the need for gating. Steroids 82:14–22.
219. Lebedeva G, Yamaguchi A, Langdon SP, Macleod K, and Harrison DJ (2012) A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen. BMC Syst Biol 6:138.
220. Lebesgue D, Chevaleyre V, Zukin RS, and Etgen AM (2009a) Estradiol rescues neurons from global ischemia-induced cell death: multiple cellular pathways of neuroprotection. Steroids 74:555–561.
221. Lebesgue D, Reyna-Neyra A, Huang X, and Etgen AM (2009b) GPR30 differentially regulates short latency responses of luteinising hormone and prolactin secretion to oestradiol. JNeuroendocrinol 21:743–752.
222. Lebesgue D, Traub M, De Butte-Smith M, Chen C, Zukin RS, Kelly MJ, and Etgen AM (2010) Acute administration of non-classical estrogen receptor agonists attenuates ischemia-induced hippocampal neuron loss in middle-aged female rats. PLoS ONE 5:e8642.
223. Leblanc K, Sexton E, Parent S, Bélanger G, Déry MC, Boucher V, and Asselin E (2007) Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. Int J Oncol 30:477–487.
224. Lenhart PM, Broselid S, Barrick CJ, Leeb-Lundberg LM, and Caron KM (2013) G-protein-coupled receptor 30 interacts with receptor activity-modifying protein 3 and confers sex-dependent cardioprotection. J Mol Endocrinol 51:191–202.
225. Levin ER (2009) G protein-coupled receptor 30: estrogen receptor or collaborator? Endocrinology 150:1563–1565.
226. Lewis-Wambi JS and Jordan VC (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11:206.
227. Li ZL, Liu JC, Liu SB, Li XQ, Yi DH, and Zhao MG (2012) Improvement of vascular function by acute and chronic treatment with the GPR30 agonist G1 in experimental diabetes mellitus. PLoS ONE 7:e38787.
228. Liggett SB (2011) Phosphorylation barcoding as a mechanism of directing GPCR signaling. Sci Signal 4:pe36.
229. Lin AH, Li RW, Ho EY, Leung GP, Leung SW, Vanhoutte PM, and Man RY (2013) Differential ligand binding affinities of human estrogen receptor-a isoforms. PLoS ONE 8:e63199.
230. Lin BC, Suzawa M, Blind RD, Tobias SC, Bulun SE, Scanlan TS, and Ingraham HA (2009) Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 69: 5415–5423.
231. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, and Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163: 2113–2126.
232. Lindsey SH, Carver KA, Prossnitz ER, and Chappell MC (2011a) Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2. Lewis female rat. J Cardiovasc Pharmacol 57:598–603.
233. Lindsey SH and Chappell MC (2011) Evidence that the G protein-coupled membrane receptor GPR30 contributes to the cardiovascular actions of estrogen. Gend Med 8: 343–354.
234. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, and Chappell MC (2009) Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 150: 3753–3758.
235. Lindsey SH, Liu L, and Chappell MC (2014) Vasodilation by GPER in mesenteric arteries involves both endothelial nitric oxide and smooth muscle cAMP signaling. Steroids 81:99–102.
236. Lindsey SH, Yamaleyeva LM, Brosnihan KB, Gallagher PE, and Chappell MC (2011b) Estrogen receptor GPR30 reduces oxidative stress and proteinuria in the salt-sensitive female mRen2.Lewis rat. Hypertension 58:665–671.
237. Liu H, Yan Y, Wen H, Jiang X, Cao X, Zhang G, and Liu G (2014) A novel estrogen receptor GPER mediates proliferation induced by 170-estradiol and selective GPER agonist G-1 in estrogen receptor a (ERa)-negative ovarian cancer cells. Cell Biol Int 38:631–638.
238. Liu S, Kilic G, Meyers MS, Navarro G, Wang Y, Oberholzer J, and Mauvais-Jarvis F (2013) Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. Diabetologia 56:370–381.
239. Liu S, Le May C, Wong WP, Ward RD, Clegg DJ, Marcelli M, Korach KS, and Mauvais-Jarvis F (2009a) Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58:2292–2302.
240. Liu X, Zhu P, Sham KW, Yuen JM, Xie C, Zhang Y, Liu Y, Li S, Huang X, and Cheng CH, et al. (2009b) Identification of a membrane estrogen receptor in zebrafish with homology to mammalian GPER and its high expression in early germ cells of the testis. Biol Reprod 80:1253–1261.
241. Liverman CS, Brown JW, Sandhir R, McCarson KE, and Berman NE (2009) Role of the oestrogen receptors GPR30 and ERalpha in peripheral sensitization: relevance to trigeminal pain disorders in women. Cephalalgia 29:729–741.
242. Lombardi G, Zarrilli S, Colao A, Paesano L, Di Somma C, Rossi F, and De Rosa M (2001) Estrogens and health in males. Mol Cell Endocrinol 178:51–55.
243. Long L, Cao Y, and Tang LD (2012) Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression. Int J Gynecol Cancer 22:539–545.
244. Lóránd T, Vigh E, and Garai J (2010) Hormonal action of plant derived and an-thropogenic non-steroidal estrogenic compounds: phytoestrogens and xenoestrogens. Curr Med Chem 17:3542–3574.
245. Lu CL, Hsieh JC, Dun NJ, Oprea TI, Wang PS, Luo JC, Lin HC, Chang FY, and Lee SD (2009) Estrogen rapidly modulates 5-hydroxytrytophan-induced visceral hy-persensitivity via GPR30 in rats. Gastroenterology 137:1040–1050.
246. Lucas TF, Royer C, Siu ER, Lazari MF, and Porto CS (2010) Expression and signaling of G protein-coupled estrogen receptor 1 (GPER) in rat sertoli cells. Biol Reprod 83:307–317.
247. Luttrell LM and Miller WE (2013) Arrestins as regulators of kinases and phosphatases. Prog Mol Biol Transl Sci 118:115–147.
248. Madeo A and Maggiolini M (2010) Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 70:6036–6046.
249. Maestes DC, Potter RM, and Prossnitz ER (1999) Differential phosphorylation paradigms dictate desensitization and internalization of the N-formyl peptide re-ceptor.J Biol Chem 274:29791–29795.
250. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, and Andò S (2004) The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279:27008–27016.
251. Maiti K, Paul JW, Read M, Chan EC, Riley SC, Nahar P, and Smith R (2011) G-1 activated membrane estrogen receptors mediate increased contractility of the human myometrium. Endocrinology 152:2488–2455.
252. Margueron R, Duong V, Bonnet S, Escande A, Vignon F, Balaguer P, and Cavaillès V (2004) Histone deacetylaseinhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens. J Mol Endocrinol 32:583–594.
253. Maric-Bilkan C, Gilbert EL, and Ryan MJ (2014) Impact of ovarian function on cardiovascular health in women: focus on hypertension. Int J Womens Health 6: 131–139.
254. Marino M, Pellegrini M, La Rosa P, and Acconcia F (2012) Susceptibility of estrogen receptor rapid responses to xenoestrogens: Physiological outcomes. Steroids 77: 910–917.
255. Marjon NA, Hu C, Hathaway HJ, and Prossnitz ER (2014) G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis. Mol Cancer Res 12:1644–1654.
256. Mårtensson UE, Salehi SA, Windahl S, Gomez MF, Swärd K, Daszkiewicz-Nilsson J, Wendt A, Andersson N, Hellstrand P, and Grände PO, et al. (2009) Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150:687–698.
257. Mary S, Fehrentz JA, Damian M, Verdié P, Martinez J, Marie J, and Banères JL (2013) How ligands and signalling proteins affect G-protein-coupled receptors’ conformational landscape. Biochem Soc Trans 41:144–147.
258. Matsuda K, Sakamoto H, Mori H, Hosokawa K, Kawamura A, Itose M, Nishi M, Prossnitz ER, and Kawata M (2008) Expression and intracellular distribution of the G protein-coupled receptor 30 in rat hippocampal formation. Neurosci Lett 441: 94–99.
259. Matthews J and Gustafsson JA (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3:281–292.
260. Mauvais-Jarvis F, Clegg DJ, and Hevener AL (2013) The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev 34:309–338.
261. McAllister CE, Creech RD, Kimball PA, Muma NA, and Li Q (2012) GPR30 is nec-essary for estradiol-induced desensitization of 5-HT1A receptor signaling in the paraventricular nucleus of the rat hypothalamus. Psychoneuroendocrinology 37: 1248–1260.
262. McDonnell DP and Wardell SE (2010) The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. Curr Opin Pharmacol 10:620–628.
263. McEwen BS, Akama KT, Spencer-Segal JL, Milner TA, and Waters EM (2012) Estrogen effects on the brain: actions beyond the hypothalamus via novel mechanisms. Behav Neurosci 126:4–16.
264. Mercier I, Mader S, and Calderone A (2003) Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 59:883–892.
265. Meyer MR, Amann K, Field AS, Hu C, Hathaway HJ, Kanagy NL, Walker MK, Barton M, and Prossnitz ER (2012a) Deletion of G protein-coupled estrogen receptor increases endothelial vasoconstriction. Hypertension 59:507–512.
266. Meyer MR, Baretella O, Prossnitz ER, and Barton M (2010) Dilation of epicardial coronary arteries by the G protein-coupled estrogen receptor agonists G-1 and ICI 182,780. Pharmacology 86:58–64.
267. Meyer MR, Clegg DJ, Prossnitz ER, and Barton M (2011a) Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol (Oxf) 203:259–269.
268. Meyer MR, Field AS, Kanagy NL, Barton M, and Prossnitz ER (2012b) GPER regulates endothelin-dependent vascular tone and intracellular calcium. Life Sci 91: 623–627.
269. Meyer MR, Fredette NC, Howard TA, Hu C, Ramesh C, Daniel C, Amann K, Arterburn JB, Barton M, and Prossnitz ER (2014) G protein-coupled estrogen receptor protects from atherosclerosis. Sci Rep 4:7564.
270. Meyer MR, Prossnitz ER, and Barton M (2011b) The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascul Pharmacol 55:17–25.
271. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, and Katzenellenbogen JA (2001) Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44:4230–4251.
272. Micevych PE and Kelly MJ (2012) Membrane estrogen receptor regulation of hypo-thalamic function. Neuroendocrinology 96:103–110.
273. Mintz PJ, Habib NA, Jones LJ, Giamas G, Lewis JS, Bowen RL, Coombes RC, and Stebbing J (2008) The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer. Cancer 113:1489–1495.
274. Minutolo F, Macchia M, Katzenellenbogen BS, and Katzenellenbogen JA (2011) Estrogen receptor b ligands: recent advances and biomedical applications. Med Res Rev 31:364–442.
275. Mitra K, Ubarretxena-Belandia I, Taguchi T, Warren G, and Engelman DM (2004) Modulation of the bilayer thickness of exocytic pathway membranes by membrane proteins rather than cholesterol. Proc Natl Acad Sci USA 101:4083–4088.
276. Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G, and Yang G (2013) GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res 15: R114.
277. Mohler ML, Narayanan R, Coss CC, Hu K, He Y, Wu Z, Hong SS, Hwang DJ, Miller DD, and Dalton JT (2010) Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications. Expert Opin Ther Pat 20:507–534.
278. Morales LB, Loo KK, Liu HB, Peterson C, Tiwari-Woodruff S, and Voskuhl RR (2006) Treatment with an estrogen receptor alpha ligand is neuroprotective in experimental autoimmune encephalomyelitis. JNeurosci 26:6823–6833.
279. Moreira IS (2014) Structural features of the G-protein/GPCR interactions. Biochim Biophys Acta 1840:16–33.
280. Moutsatsou P (2007) The spectrum of phytoestrogens in nature: our knowledge is expanding. Hormones (Athens) 6:173–193.
281. Muller RE, Johnston TC, Traish AM, and Wotiz HH (1979) Studies on the mechanism of estradiol uptake by rat uterine cells and on estradiol binding to uterine plasma membranes. Adv Exp Med Biol 117:401–421.
282. Munson PJ and Rodbard D (1988) An exact correction to the “Cheng-Prusoff~ cor-rection. J Recept Res 8:533–546.
283. Murata T, Dietrich HH, Xiang C, and Dacey RG Jr (2013) G protein-coupled estrogen receptor agonist improves cerebral microvascular function after hypoxia/ reoxygenation injury in male and female rats. Stroke 44:779–785.
284. Nayak TK, Dennis MK, Ramesh C, Burai R, Atcher RW, Sklar LA, Norenberg JP, Hathaway HJ, Arterburn JB, and Prossnitz ER (2010) Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents. ACS Chem Biol 5:681–690.
285. Nayak TK, Hathaway HJ, Ramesh C, Arterburn JB, Dai D, Sklar LA, Norenberg JP, and Prossnitz ER (2008) Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers. J Nucl Med 49:978–986.
286. Nayak TK, Ramesh C, Hathaway HJ, Norenberg JP, Arterburn JB, and Prossnitz ER (2014) GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding. Mol Cancer Res 12:1635–1643.
287. Nelson ER, Wardell SE, and McDonnell DP (2013) The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: implications for the treatment and prevention of osteoporosis. Bone 53:42–50.
288. Newbold RR (2004) Lessons learned from perinatal exposure to diethylstilbestrol. Toxicol Appl Pharmacol 199:142–150.
289. Niino M, Hirotani M, Fukazawa T, Kikuchi S, and Sasaki H (2009) Estrogens as potential therapeutic agents in multiple sclerosis. Cent Nerv Syst Agents Med Chem 9:87–94.
290. Nilsson S and Gustafsson JA (2011) Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Ther 89:44–55.
291. Nilsson S, Koehler KF, and Gustafsson JA (2011) Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 10:778–792.
292. Nishimura Y, Nakai Y, Tanaka A, Nagao T, and Fukushima N (2014) Long-term exposure of 3T3 fibroblast cells to endocrine disruptors alters sensitivity to oxidative injury. Cell Biol Int 38:868–874.
293. Noda-Seino H, Sawada K, Hayakawa J, Ohyagi-Hara C, Mabuchi S, Takahashi K, Nishio Y, Sakata M, Kurachi H, and Kimura T (2013) Estradiol and raloxifene induce the proliferation of osteoblasts through G-protein-coupled receptor GPR30. J Endocrinol Invest 36:21–27.
294. Noel SD, Keen KL, Baumann DI, Filardo EJ, and Terasawa E (2009) Involvement of G protein-coupled receptor 30 (GPR30) in rapid action of estrogen in primate LHRH neurons. Mol Endocrinol 23:349–359.
295. O’Dowd BF, Nguyen T, Marchese A, Cheng R, Lynch KR, Heng HH, Kolakowski LF Jr, and George SR (1998) Discovery of three novel G-protein-coupled receptor genes. Genomics 47:310–313.
296. Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Rizzo P, Marino A, D’Amico M, Sponziello F, and Mazzoni E, et al. (2010) Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev 36 (Suppl 3):S67–S71.
297. Ososki AL and Kennelly EJ (2003) Phytoestrogens: a review of the present state of research. Phytother Res 17:845–869.
298. Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, Schwarz G, Altmann H, Klewer M, and Schoor M, et al. (2009) GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod 80:34–41.
299. Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, and Nubbemeyer R, et al. (2008) G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 149:4846–4856.
300. Owen MR, Sherratt JA, and Myers SR (1999) How far can a juxtacrine signal travel? Proc Biol Sci 266:579–585.
301. Owman C, Blay P, Nilsson C, and Lolait SJ (1996) Cloning of human cDNA encoding a novel heptahelix receptor expressed in Burkitt’s lymphoma and widely distributed in brain and peripheral tissues. Biochem Biophys Res Commun 228: 285–292.
302. Palaszynski KM, Liu H, Loo KK, and Voskuhl RR (2004) Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol 149:84–89.
303. Palmieri D, Perego P, and Palombo D (2012) Apigenin inhibits the TNFa-induced expression of eNOS and MMP-9 via modulating Akt signalling through oestrogen receptor engagement. Mol Cell Biochem 371:129–136.
304. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, and Picard D (2009) Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28:523–532.
305. Pang Y, Dong J, and Thomas P (2008) Estrogen signaling characteristics of Atlantic croaker G protein-coupled receptor 30 (GPR30) and evidence it is involved in maintenance of oocyte meiotic arrest. Endocrinology 149:3410–3426.
306. Pang Y and Thomas P (2010) Role of G protein-coupled estrogen receptor 1, GPER, in inhibition of oocyte maturation by endogenous estrogens in zebrafish. Dev Biol 342: 194–206.
307. Patel VH, Chen J, Ramanjaneya M, Karteris E, Zachariades E, Thomas P, Been M, and Randeva HS (2010) G-protein coupled estrogen receptor 1 expression in rat and human heart: Protective role during ischaemic stress. Int J Mol Med 26: 193–199.
308. Paterni I, Bertini S, Granchi C, Macchia M, and Minutolo F (2013) Estrogen receptor ligands: a patent review update. Expert Opin Ther Pat 23:1247–1271.
309. Paterni I, Granchi C, Katzenellenbogen JA, and Minutolo F (2014) Estrogen receptors alpha (ERalpha) and beta (ERbeta): Subtype-selective ligands and clinical potential. Steroids 90:13–29.
310. Pedram A, Razandi M, and Levin ER (2006) Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 20:1996–2009.
311. Pedram A, Razandi M, Lewis M, Hammes S, and Levin ER (2014) Membrane-localized estrogen receptor a is required for normal organ development and function. Dev Cell 29:482–490.
312. Pedram A, Razandi M, O’Mahony F, Harvey H, Harvey BJ, and Levin ER (2013) Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling. Sci Signal 6:ra36.
313. Pérez-Torres I, Guarner V, El Hafidi M, and Baños G (2011) Sex hormones, metabolic syndrome and kidney. Curr Top Med Chem 11:1694–1705.
314. Pernis AB (2007) Estrogen and CD4+ T cells. Curr Opin Rheumatol 19:414–420.
315. Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ, and Prossnitz ER (2013) G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstet Gynecol Int 2013:472720.
316. Peyton C and Thomas P (2011) Involvement of epidermal growth factor receptor signaling in estrogen inhibition of oocyte maturation mediated through the G protein-coupled estrogen receptor (Gper) in zebrafish (Danio rerio). Biol Reprod 85: 42–50.
317. Pietras RJ and Szego CM (1975) Endometrial cell calcium and oestrogen action. Nature 253:357–359.
318. Pinkerton JV and Goldstein SR (2010) Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 17:642–653.
319. Plante BJ, Lessey BA, Taylor RN, Wang W, Bagchi MK, Yuan L, Scotchie J, Fritz MA, and Young SL (2012) G protein-coupled estrogen receptor (GPER) expression in normal and abnormal endometrium. Reprod Sci 19:684–693.
320. Platta HW and Stenmark H (2011) Endocytosis and signaling. Curr Opin Cell Biol 23:393–403.
321. Prossnitz ER (2004) Novel roles for arrestins in the post-endocytic trafficking of G protein-coupled receptors. Life Sci 75:893–899.
322. Prossnitz ER (2012) G protein-coupled estrogen receptor: a new therapeutic target in stroke and traumatic brain/spinal cord injury? Crit Care Med 40:3323–3325.
323. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, and Hathaway HJ (2008) Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 70:165–190.
324. Prossnitz ER and Barton M (2009) Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER. Prostaglandins Other Lipid Mediat 89:89–97.
325. Prossnitz ER and Barton M (2011) The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol 7:715–726.
326. Prossnitz ER and Barton M (2014) Estrogen biology: new insights into GPER function and clinical opportunities. Mol Cell Endocrinol 389:71–83.
327. Prossnitz ER and Maggiolini M (2009a) Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 308:32–38.
328. Prossnitz ER and Maggiolini M (2009b) Non-genomic signaling by steroids. Mol Cell Endocrinol 308:1–2.
329. Prossnitz ER and Sklar LA (2006) Modulation of GPCR conformations by ligands, G-proteins, and arrestins. Ernst Schering Found Symp Proc 2006:211–228.
330. Pupo M, Pisano A, Lappano R, Santolla MF, De Francesco EM, Abonante S, Rosano C, and Maggiolini M (2012) Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect 120:1177–1182.
331. Pupo M, Vivacqua A, Perrotta I, Pisano A, Aquila S, Abonante S, Gasperi-Campani A, Pezzi V, and Maggiolini M (2013) The nuclear localization signal is required for nuclear GPER translocation and function in breast Cancer-Associated Fibroblasts (CAFs). Mol Cell Endocrinol 376:23–32.
332. Qiu J, Bosch MA, Tobias SC, Krust A, Graham SM, Murphy SJ, Korach KS, Chambon P, Scanlan TS, and Rønnekleiv OK, et al. (2006) A G-protein-coupled estrogen receptor is involved in hypothalamic control of energy homeostasis. J Neurosci 26:5649–5655.
333. Ramesh C, Bryant B, Nayak T, Revankar CM, Anderson T, Carlson KE, Katzenellenbogen JA, Sklar LA, Norenberg JP, and Prossnitz ER, et al. (2006) Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ERalpha/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates. JAm Chem Soc 128:14476–14477.
334. Ramesh C, Nayak TK, Burai R, Dennis MK, Hathaway HJ, Sklar LA, Prossnitz ER, and Arterburn JB (2010) Synthesis and characterization of iodinated tetrahy-droquinolines targeting the G protein-coupled estrogen receptor GPR30. J Med Chem 53:1004–1014.
335. Ray A and Ficek M (2012) Immunomodulatory effects of anti-estrogenic drugs. Acta Pharm 62:141–155.
336. Raz L, Khan MM, Mahesh VB, Vadlamudi RK, and Brann DW (2008) Rapid estrogen signaling in the brain. Neurosignals 16:140–153.
337. Reiter E, Ahn S, Shukla AK, and Lefkowitz RJ (2012) Molecular mechanism of b-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52:179–197.
338. Rettberg JR, Yao J, and Brinton RD (2014) Estrogen: a master regulator of bioenergetic systems in the brain and body. Front Neuroendocrinol 35:8–30.
339. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, and Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625–1630.
340. Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C, Sklar LA, Arterburn JB, and Prossnitz ER (2007) Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol 2:536–544.
341. Rickert EL, Oriana S, Hartman-Frey C, Long X, Webb TT, Nephew KP, and Weatherman RV (2010) Synthesis and characterization of fluorescent 4 hydroxytamoxifen conjugates with unique antiestrogenic properties. Bioconjug Chem 21:903–910.
342. Rivera-Guevara C, Pérez-Alvarez V, García-Becerra R, Ordaz-Rosado D, MoralesRíos MS, Hernández-Gallegos E, Cooney AJ, Bravo-Gómez ME, Larrea F, and Camacho J (2010) Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem 18:5593–5601.
343. Roepke TA, Qiu J, Bosch MA, Rønnekleiv OK, and Kelly MJ (2009) Cross-talk between membrane-initiated and nuclear-initiated oestrogen signalling in the hypothalamus. JNeuroendocrinol 21:263–270.
344. Rosano C, Lappano R, Santolla MF, Ponassi M, Donadini A, and Maggiolini M (2012) Recent advances in the rationale design of GPER ligands. Curr Med Chem 19: 6199–6206.
345. Rosenbaum DM, Rasmussen SG, and Kobilka BK (2009) The structure and function of G-protein-coupled receptors. Nature 459:356–363.
346. Rosner D and Markowitz G (2013) Persistent pollutants: a brief history of the discovery of the widespread toxicity of chlorinated hydrocarbons. Environ Res 120: 126–133.
347. Rowlands DJ, Chapple S, Siow RC, and Mann GE (2011) Equol-stimulated mito-chondrial reactive oxygen species activate endothelial nitric oxide synthase and redox signaling in endothelial cells: roles for F-actin and GPR30. Hypertension 57: 833–840.
348. Rudolf FO and Kadokawa H (2013) Expression of estradiol receptor, GPR30, in bovine anterior pituitary and effects of GPR30 agonist on GnRH-induced LH secretion. Anim Reprod Sci 139:9–17.
349. Sakamoto H, Matsuda K, Hosokawa K, Nishi M, Morris JF, Prossnitz ER, and Kawata M (2007) Expression of G protein-coupled receptor-30, a G protein-coupled membrane estrogen receptor, in oxytocin neurons of the rat paraventricular and supraoptic nuclei. Endocrinology 148:5842–5850.
350. Sakiani S, Olsen NJ, and Kovacs WJ (2013) Gonadal steroids and humoral immunity. Nat Rev Endocrinol 9:56–62.
351. Samartzis N, Samartzis EP, Noske A, Fedier A, Dedes KJ, Caduff R, Fink D, and Imesch P (2012) Expression of the G protein-coupled estrogen receptor (GPER) in endometriosis: a tissue microarray study. Reprod Biol Endocrinol 10:30.
352. Sandra N, Ester P, Marie-Agnès P, Robert M, and Olivier H (2012) The DHEA metabolite 7b-hydroxy-epiandrosterone exerts anti-estrogenic effects on breast cancer cell lines. Steroids 77:542–551.
353. Santolla MF, Lappano R, De Marco P, Pupo M, Vivacqua A, Sisci D, Abonante S, Iacopetta D, Cappello AR, and Dolce V, et al. (2012) G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17b-estradiol in cancer cells and cancer-associated fibroblasts. J Biol Chem 287:43234–43245.
354. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, and Wang Z (2003) Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem 278:41998–42005.
355. Scaling AL, Prossnitz ER, and Hathaway HJ (2014) GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast. Horm Cancer 5:146–160.
356. Schug TT, Janesick A, Blumberg B, and Heindel JJ (2011) Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol 127:204–215.
357. Schuler MA, Denisov IG, and Sligar SG (2013) Nanodiscs as a new tool to examine lipid-protein interactions. Methods Mol Biol 974:415–433.
358. Schultz-Norton JR, Ziegler YS, and Nardulli AM (2011) ERa-associated protein networks. Trends Endocrinol Metab 22:124–129.
359. Seifert R (2013) Functional selectivity of G-protein-coupled receptors: from recombinant systems to native human cells. Biochem Pharmacol 86:853–861.
360. Sengupta S and Jordan VC (2008) Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol 630:206–219.
361. Seo JW, Chi DY, Dence CS, Welch MJ, and Katzenellenbogen JA (2007) Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor. Nucl Med Biol 34:383–390.
362. Shanle EK and Xu W (2011) Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem Res Toxicol 24: 6–19.
363. Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ, and Prossnitz ER (2013) GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proin-flammatory state. Endocrinology 154:4136–4145.
364. Sharma G and Prossnitz ER (2011) Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic beta-cells. Endocrinology 152:3030–3039.
365. Sharma VK, Anquandah GA, Yngard RA, Kim H, Fekete J, Bouzek K, Ray AK, and Golovko D (2009) Nonylphenol, octylphenol, and bisphenol-A in the aquatic environment: a review on occurrence, fate, and treatment. J Environ Sci Health A Tox Hazard Subst Environ Eng 44:423–442.
366. Shearer KE, Rickert EL, Peterson AC, and Weatherman RV (2012) Dissecting rapid estrogen signaling with conjugates. Steroids 77:968–973.
367. Shelnutt S, Kind J, and Allaben W (2013) Bisphenol A: Update on newly developed data and how they address NTP’s 2008 finding of “Some Concern”. Food Chem Toxicol 57:284–295.
368. Sheng ZG, Huang W, Liu YX, and Zhu BZ (2013) Bisphenol A at a low concentration boosts mouse spermatogonial cell proliferation by inducing the G protein-coupled receptor 30 expression. Toxicol Appl Pharmacol 267:88–94.
369. Sheng ZG and Zhu BZ (2011) Low concentrations of bisphenol A induce mouse spermatogonial cell proliferation by G protein-coupled receptor 30 and estrogen receptor-a. Environ Health Perspect 119:1775–1780.
370. Shirvani H, Gätà G, and Marullo S (2012) Regulated GPCR trafficking to the plasma membrane: general issues and the CCR5 chemokine receptor example. Subcell Biochem 63:97–111.
371. Siegfried JM, Hershberger PA, and Stabile LP (2009) Estrogen receptor signaling in lung cancer. Semin Oncol 36:524–531.
372. Simpson E, Rubin G, Clyne C, Robertson K, O’Donnell L, Davis S, and Jones M (1999) Local estrogen biosynthesis in males and females. EndocrRelat Cancer 6:131–137.
373. Singh AB and Harris RC (2005) Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 17:1183–1193.
374. Singleton DW and Khan SA (2003) Xenoestrogen exposure and mechanisms of en-docrine disruption. Front Biosci 8:s110–s118.
375. Sirianni R, Chimento A, Ruggiero C, De Luca A, Lappano R, Andò S, Maggiolini M, and Pezzi V (2008) The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 17beta-estradiol on mouse spermatogonial GC-1 cell line. Endocrinology 149:5043–5051.
376. Skaddan MB, Wüst FR, Jonson S, Syhre R, Welch MJ, Spies H, and Katzenellenbogen JA (2000) Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7alphasubstituted estradiol complexes. Nucl Med Biol 27:269–278.
377. Sklar LA, Vilven J, Lynam E, Neldon D, Bennett TA, and Prossnitz E (2000) Solu-bilization and display of G protein-coupled receptors on beads for real-time fluo-rescence and flow cytometric analysis. Biotechniques 28:976–980, 982–985.
378. Smith CL and O Malley BW (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45–71.
379. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, and Prossnitz ER (2009) GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 114:465–471.
380. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, and Prossnitz ER (2007) GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 196:386.
381. Sömjen D, Waisman A, and Kaye AM (1996) Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo. J Steroid Biochem Mol Biol 59:389–396.
382. Srivastava DP and Evans PD (2013) G-protein oestrogen receptor 1: trials and tribulations of a membrane oestrogen receptor. JNeuroendocrinol 25:1219–1230.
383. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, and Katzenellenbogen JA (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43: 4934–4947.
384. Stein DG and Hoffman SW (2003) Estrogen and progesterone as neuroprotectiveagents in the treatment of acute brain injuries. Pediatr Rehabil 6:13–22.
385. Stephany RW (2010) Hormonal growth promoting agents in food producing animals. Handb Exp Pharmacol 195:355–367.
386. Stevis PE, Deecher DC, Suhadolnik L, Mallis LM, and Frail DE (1999) Differential effects of estradiol and estradiol-BSA conjugates. Endocrinology 140:5455–5458.
387. Sukocheva O, Wadham C, Holmes A, Albanese N, Verrier E, Feng F, Bernal A, Derian CK, Ullrich A, and Vadas MA, et al. (2006) Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol 173:301–310.
388. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, and Katzenellenbogen BS (2002) Antagonists selective for estrogen receptor alpha. Endocrinology 143:941–947.
389. Szego CM and Davis JS (1967) Adenosine 3',5'-monophosphate in rat uterus: acute elevation by estrogen. Proc Natl Acad Sci USA 58:1711–1718.
390. Taguchi Y, Koslowski M, and Bodenner DL (2004) Binding of estrogen receptor with estrogen conjugated to bovine serum albumin (BSA). Nucl Recept 2:5.
391. Takada Y, Kato C, Kondo S, Korenaga R, and Ando J (1997) Cloning of cDNAs encoding G protein-coupled receptor expressed in human endothelial cells exposed to fluid shear stress. Biochem Biophys Res Commun 240:737–741.
392. Takayanagi S, Tokunaga T, Liu X, Okada H, Matsushima A, and Shimohigashi Y (2006) Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity. Toxicol Lett 167: 95–105.
393. Taylor SE, Martin-Hirsch PL, and Martin FL (2010) Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett 288:133–148.
394. Temple JL and Wray S (2005) Bovine serum albumin-estrogen compounds differentially alter gonadotropin-releasing hormone-1 neuronal activity. Endocrinology 146:558–563.
395. Teng J, Wang ZY, Prossnitz ER, and Bjorling DE (2008) The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology 149: 4024–4034.
396. Terasawa E, Noel SD, and Keen KL (2009) Rapid action of oestrogen in luteinising hormone-releasing hormone neurones: the role of GPR30. J Neuroendocrinol 21: 316–321.
397. Thomas P, Alyea R, Pang Y, Peyton C, Dong J, and Berg AH (2010) Conserved estrogen binding and signaling functions of the G protein-coupled estrogen receptor 1 (GPER) in mammals and fish. Steroids 75:595–602.
398. Thomas P and Dong J (2006) Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 102:175–179.
399. Thomas P, Pang Y, Filardo EJ, and Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146: 624–632.
400. Thornton JW (2001) Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions. Proc Natl Acad Sci USA 98:5671–5676.
401. Thornton JW, Need E, and Crews D (2003) Resurrecting the ancestral steroid receptor: ancient origin of estrogen signaling. Science 301:1714–1717.
402. Tica AA, Dun EC, Tica OS, Gao X, Arterburn JB, Brailoiu GC, Oprea TI, and Brailoiu E (2011) G protein-coupled estrogen receptor 1-mediated effects in the rat myometrium. Am J Physiol Cell Physiol 301:C1262–C1269.
403. Toran-Allerand CD (2004) Minireview: A plethora of estrogen receptors in the brain: where will it end? Endocrinology 145:1069–1074.
404. Totta P, Pesiri V, Marino M, and Acconcia F (2014) Lysosomal function is involved in 17b-estradiol-induced estrogen receptor a degradation and cell proliferation. PLoS ONE 9:e94880.
405. Van Craenenbroeck K (2012) GPCR oligomerization: contribution to receptor bio-genesis. Subcell Biochem 63:43–65.
406. Vaucher L, Funaro MG, Mehta A, Mielnik A, Bolyakov A, Prossnitz ER, Schlegel PN, and Paduch DA (2014) Activation of GPER-1 estradiol receptor downregulates production of testosterone in isolated rat Leydig cells and adult human testis. PLoS ONE 9:e92425.
407. Verenich S and Gerk PM (2010) Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm 7:2030–2039.
408. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Andò S, and Maggiolini M (2006a) 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein-coupled receptor GPR30. Mol Pharmacol 70:1414–1423.
409. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, and Maggiolini M (2006b) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20:631–646.
410. Wakeling AE and Bowler J (1992) ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 43:173–177.
411. Walther C and Ferguson SS (2013) Arrestins: role in the desensitization, sequestration, and vesicular trafficking of G protein-coupled receptors. Prog Mol Biol Transl Sci 118:93–113.
412. Wang C, Dehghani B, Li Y, Kaler LJ, Proctor T, Vandenbark AA, and Offner H (2009) Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol 182:3294–3303.
413. Wang C, Dehghani B, Magrisso IJ, Rick EA, Bonhomme E, Cody DB, Elenich LA, Subramanian S, Murphy SJ, and Kelly MJ, et al. (2008a) GPR30 contributes to estrogen-induced thymic atrophy. Mol Endocrinol 22:636–648.
414. Wang C, Lv X, He C, Hua G, Tsai MY, and Davis JS (2013) The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization. Cell Death Dis 4:e869.
415. Wang C, Prossnitz ER, and Roy SK (2008b) G protein-coupled receptor 30 expression is required for estrogen stimulation of primordial follicle formation in the hamster ovary. Endocrinology 149:4452–4461.
416. Wang H, Jessup JA, Lin MS, Chagas C, Lindsey SH, and Groban L (2012) Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats. Cardiovasc Res 94:96–104.
417. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, and Deuel TF (2006) A variant of estrogen receptor-alpha, hER-alpha36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci USA 103: 9063–9068.
418. Washburn N, Borgquist A, Wang K, Jeffery GS, Kelly MJ, and Wagner EJ (2013) Receptor subtypes and signal transduction mechanisms contributing to the estrogenic attenuation of cannabinoid-induced changes in energy homeostasis. Neuro-endocrinology 97:160–175.
419. Watson CS, Hu G, and Paulucci-Holthauzen AA (2014) Rapid actions of xenoestrogens disrupt normal estrogenic signaling. Steroids 81:36–42.
420. Watson CS, Jeng YJ, Hu G, Wozniak A, Bulayeva N, and Guptarak J (2012) Estrogen-and xenoestrogen-induced ERK signaling in pituitary tumor cells involves estrogen receptor-a interactions with G protein-ai and caveolin I. Steroids 77:424–432.
421. Weißenborn C, Ignatov T, Ochel HJ, Costa SD, Zenclussen AC, Ignatova Z, and Ignatov A (2014a) GPER functions as a tumor suppressor in triple-negative breast cancer cells. J Cancer Res Clin Oncol 140:713–723.
422. Weißenborn C, Ignatov T, Poehlmann A, Wege AK, Costa SD, Zenclussen AC, and Ignatov A (2014b) GPER functions as a tumor suppressor in MCF-7 and SKBR-3 breast cancer cells. J Cancer Res Clin Oncol 140:663–671.
423. Williams C and Lin CY (2013) Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedicalscience 7:370.
424. Witkowska HE, Carlquist M, Engström O, Carlsson B, Bonn T, Gustafsson JA, and Shackleton CH (1997) Characterization of bacterially expressed rat estrogen receptor beta ligand binding domain by mass spectrometry: structural comparison with estrogen receptor alpha. Steroids 62:621–631.
425. Woehler A and Ponimaskin EG (2009) G protein—mediated signaling: same receptor, multiple effectors. Curr Mol Pharmacol 2:237–248.
426. Wong JK, Le HH, Zsarnovszky A, and Belcher SM (2003) Estrogens and ICI182,780 (Faslodex) modulate mitosis and cell death in immature cerebellar neurons via rapid activation of p44/p42 mitogen-activated protein kinase. J Neurosci 23: 4984–4995.
427. Wong RL and Walker CL (2013) Molecular pathways: environmental estrogens activate nongenomic signaling to developmentally reprogram the epigenome. Clin Cancer Res 19:3732–3737.
428. Wong SK (2003) G protein selectivity is regulated by multiple intracellular regions of GPCRs. Neurosignals 12:1–12.
429. Wootten D, Christopoulos A, and Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12:630–644.
430. Wu Q, Chambliss K, Umetani M, Mineo C, and Shaul PW (2011a) Non-nuclear estrogen receptor signaling in the endothelium. J Biol Chem 286:14737–14743.
431. Wu TW, Chen S, and Brinton RD (2011b) Membrane estrogen receptors mediate calcium signaling and MAP kinase activation in individual hippocampal neurons. Brain Res 1379:34–43.
432. Xu H, Qin S, Carrasco GA, Dai Y, Filardo EJ, Prossnitz ER, Battaglia G, Doncarlos LL, and Muma NA (2009) Extra-nuclear estrogen receptor GPR30 regulates serotonin function in rat hypothalamus. Neuroscience 158:1599–1607.
433. Yager JD and Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270–282.
434. Yates MA, Li Y, Chlebeck PJ, and Offner H (2010) GPR30, but not estrogen receptor-alpha, is crucial in the treatment of experimental autoimmune encephalomyelitis by oral ethinyl estradiol. BMC Immunol 11:20.
435. Yoo J, Dence CS, Sharp TL, Katzenellenbogen JA, and Welch MJ (2005) Synthesis of an estrogen receptor beta-selective radioligand: 5-[18F]fluoro-(2R,3S)-2,3-bis(4- hydroxyphenyl)pentanenitrile and comparison of in vivo distribution with 16alpha-[18F]fluoro-17beta-estradiol. J Med Chem 48:6366–6378.
436. Yoon K, Kwack SJ, Kim HS, and Lee BM (2014) Estrogenic endocrine-disrupting chemicals: molecular mechanisms of actions on putative human diseases. JToxicol Environ Health B Crit Rev 17:127–174.
437. Yu X, Ma H, Barman SA, Liu AT, Sellers M, Stallone JN, Prossnitz ER, White RE, and Han G (2011) Activation of G protein-coupled estrogen receptor induces endothelium-independent relaxation of coronary artery smooth muscle. Am J Physiol Endocrinol Metab 301:E882–E888.
438. Yuguchi H, Tanabe A, Hayashi A, Tanaka Y, Okuda K, Yamashita Y, Terai Y, and Ohmichi M (2013) The expression status of G protein-coupled receptor GPR30 is associated with the clinical characteristics of endometriosis. Endocr Res 38: 223–231.
439. Zhang B, Subramanian S, Dziennis S, Jia J, Uchida M, Akiyoshi K, Migliati E, Lewis AD, Vandenbark AA, and Offner H, et al. (2010) Estradiol and G1 reduce infarct size and improve immunosuppression after experimental stroke. J Immunol 184: 4087–4094.
440. Zhang KS, Chen HQ, Chen YS, Qiu KF, Zheng XB, Li GC, Yang HD, and Wen CJ (2014a) Bisphenol A stimulates human lung cancer cell migration via upregulation of matrix metalloproteinases by GPER/EGFR/ERK1/2 signal pathway. Biomed Pharmacother 68:1037–1043.
441. Zhang QG, Wang R, Tang H, Dong Y, Chan A, Sareddy GR, Vadlamudi RK, and Brann DW (2014b) Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus. Mol Cell Endocrinol 389:84–91.
442. Zhang X, Li JH, Duan SX, Lin QJ, Ke S, Ma L, Huang TH, and Jiang XW (2014c) G protein-coupled estrogen receptor-protein kinase A-ERK-CREB signaling pathway is involved in the regulation of mouse gubernaculum testis cells by di-ethylstilbestrol. Arch Environ Contam Toxicol 67:97–103.
443. Zhao L, O Neill K, and Brinton RD (2006) Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J Pharmacol Exp Ther 319:1124–1132.
444. Zhu BT, Han GZ, Shim JY, Wen Y, and Jiang XR (2006a) Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology 147:4132–4150.
445. Zhu T, Gobeil F, Vazquez-Tello A, Leduc M, Rihakova L, Bossolasco M, Bkaily G, Peri K, Varma DR, and Orvoine R, et al. (2006b) Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Can J Physiol Pharmacol 84:377–391.
446. Zhuang S, Zhang J, Wen Y, Zhang C, and Liu W (2012) Distinct mechanisms of endocrine disruption of DDT-related pesticides toward estrogen receptor a and estrogen-related receptor g. Environ Toxicol Chem 31:2597–2605.
447. Zucchetti AE, Barosso IR, Boaglio AC, Basiglio CL, Miszczuk G, Larocca MC, Ruiz ML, Davio CA, Roma MG, and Crocenzi FA, et al. (2014) G-protein-coupled receptor 30/adenylyl cyclase/protein kinase A pathway is involved in estradiol 17ß-D-glucuronide-induced cholestasis. Hepatology 59:1016–1029.